Arcus Biosciences (RCUS) to Release Earnings on Wednesday

Arcus Biosciences (NYSE:RCUS) is scheduled to be announcing its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.97) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, February 21st. The company reported ($1.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.01. The firm had revenue of $31.00 million for the quarter, compared to the consensus estimate of $28.30 million. Arcus Biosciences had a negative return on equity of 57.17% and a negative net margin of 262.39%. The company’s revenue for the quarter was down 8.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.93) earnings per share. On average, analysts expect Arcus Biosciences to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arcus Biosciences Trading Up 1.6 %

NYSE:RCUS opened at $15.95 on Tuesday. Arcus Biosciences has a 1 year low of $12.95 and a 1 year high of $25.47. The stock has a fifty day moving average price of $17.18 and a two-hundred day moving average price of $16.59.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on RCUS. Wedbush reissued an “outperform” rating and set a $30.00 price objective on shares of Arcus Biosciences in a report on Thursday, February 22nd. Mizuho decreased their price target on Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, January 30th. Finally, Truist Financial restated a “buy” rating and issued a $50.00 price target on shares of Arcus Biosciences in a report on Monday, March 25th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.25.

Insider Activity at Arcus Biosciences

In related news, COO Jennifer Jarrett sold 11,551 shares of the stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $17.55, for a total transaction of $202,720.05. Following the sale, the chief operating officer now owns 215,253 shares of the company’s stock, valued at $3,777,690.15. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, COO Jennifer Jarrett sold 11,551 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $17.55, for a total value of $202,720.05. Following the completion of the transaction, the chief operating officer now owns 215,253 shares of the company’s stock, valued at $3,777,690.15. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Juan C. Jaen sold 3,900 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $20.06, for a total transaction of $78,234.00. Following the sale, the president now owns 1,211,365 shares in the company, valued at approximately $24,299,981.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 53,455 shares of company stock valued at $1,014,779. 12.30% of the stock is owned by corporate insiders.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.